Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
VEGFD Biologics Sequence Review Report 2026: Vascular endothelial growth factor D Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
VEGFD Biologics Sequence Review Report 2026: Vascular endothelial growth factor D Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of VEGFD protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF16 Biologics Sequence Review Report 2026: Fibroblast growth factor 16 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF16 Biologics Sequence Review Report 2026: Fibroblast growth factor 16 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
FGF10 Biologics Sequence Review Report 2026: Fibroblast growth factor 10 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
FGF10 Biologics Sequence Review Report 2026: Fibroblast growth factor 10 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of FGF10 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCL16 Biologics Sequence Review Report 2026: C-C motif chemokine 16 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCL16 Biologics Sequence Review Report 2026: C-C motif chemokine 16 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CCL16 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCL25 Biologics Sequence Review Report 2026: C-C motif chemokine 25 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCL25 Biologics Sequence Review Report 2026: C-C motif chemokine 25 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CCL25 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ACKR5 Biologics Sequence Review Report 2026: Atypical chemokine receptor 5 Similarity and Patent-Risk Signals
8 min read
ACKR5 Biologics Sequence Review Report 2026: Atypical chemokine receptor 5 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ACKR5 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
TNFSF11 Biologics Sequence Review Report 2026: Tumor necrosis factor ligand superfamily member 11 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
TNFSF11 Biologics Sequence Review Report 2026: Tumor necrosis factor ligand superfamily member 11 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of TNFSF11 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
ACKR2 Biologics Sequence Review Report 2026: Atypical chemokine receptor 2 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
ACKR2 Biologics Sequence Review Report 2026: Atypical chemokine receptor 2 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of ACKR2 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCL21 Biologics Sequence Review Report 2026: C-C motif chemokine 21 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCL21 Biologics Sequence Review Report 2026: C-C motif chemokine 21 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CCL21 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CXCR6 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 6 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CXCR6 Biologics Sequence Review Report 2026: C-X-C chemokine receptor type 6 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CXCR6 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
CCL24 Biologics Sequence Review Report 2026: C-C motif chemokine 24 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
CCL24 Biologics Sequence Review Report 2026: C-C motif chemokine 24 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of CCL24 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →
GPR25 Biologics Sequence Review Report 2026: C-X-C chemokine receptor GPR25 Similarity and Patent-Risk Signals
Latest Hotspot
8 min read
GPR25 Biologics Sequence Review Report 2026: C-X-C chemokine receptor GPR25 Similarity and Patent-Risk Signals
4 August 2026
A Biology Modality MCP review of GPR25 protein-sequence similarity, pairwise alignment, patent-sequence signals and antibody–antigen evidence.
Read →